J9355 HCPCS Level II code: Injection, trastuzumab, excludes biosimilar, 10 mg
J9355 is the HCPCS code for “Injection, trastuzumab, excludes biosimilar, 10 mg” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J9355Injection, trastuzumab, excludes biosimilar, 10 mg
Short description: Inj trastuzumab excl biosimi
HCPCS · United States
Medicare details
The indicators CMS publishes with J9355 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- ASC
- Approved for ambulatory surgical centers
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Other drugs
- Added
- Jan 1, 2000
Where J9355 sits
- 1J codesDrugs administered other than orally
- 2Active code J9355Injection, trastuzumab, excludes biosimilar, 10 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J9355 mean?
J9355 is the HCPCS code for “Injection, trastuzumab, excludes biosimilar, 10 mg” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J9355?
CMS lists J9355’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J9355
All J codesJ9349Injection, tafasitamab-cxix, 2 mgJ9350Injection, mosunetuzumab-axgb, 1 mgJ9351Injection, topotecan, 0.1 mgJ9352Injection, trabectedin, 0.1 mgJ9353Injection, margetuximab-cmkb, 5 mgJ9354Injection, ado-trastuzumab emtansine, 1 mgJ9356Injection, trastuzumab, 10 mg and hyaluronidase-oyskJ9357Injection, valrubicin, intravesical, 200 mgJ9358Injection, fam-trastuzumab deruxtecan-nxki, 1 mgJ9359Injection, loncastuximab tesirine-lpyl, 0.075 mgJ9360Injection, vinblastine sulfate, 1 mgJ9361Injection, efbemalenograstim alfa-vuxw, 0.5 mg